GLAND PHARMA | USFDA conducted Good Manufacturing Practice (GMP) Inspection at the Company’s Dundigal Facility at Hyderabad between 03rd July, 2023 and 14th July, 2023. The inspection was concluded with one 483 Observation. The corrective and preventive actions for this observation will be submitted to the US FDA within the stipulated period, the company said. The observation issued is neither a repeated observation nor related to data integrity, it added.